NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
Equillium Inc (F: 0FY)
0FY Technical Analysis
4
As on 20th Nov 2024 0FY STOCK Price closed @ 0.68 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.98 & Sell for SHORT-TERM with Stoploss of 0.69 we also expect STOCK to react on Following IMPORTANT LEVELS. |
0FYSTOCK Price
Open | 0.68 | Change | Price | % |
High | 0.68 | 1 Day | -0.48 | -41.38 |
Low | 0.68 | 1 Week | -0.52 | -43.33 |
Close | 0.68 | 1 Month | -0.01 | -1.45 |
Volume | 1080 | 1 Year | 0.10 | 17.24 |
52 Week High 2.70 | 52 Week Low 0.42 |
F Germany Most Active Stocks
IMU | 0.10 | -99.65% |
IMU | 0.10 | -99.65% |
IMU | 0.10 | -99.65% |
IMU | 0.10 | -99.65% |
IMU | 0.10 | -99.65% |
ENB | 47.60 | -0.92% |
TEF | 3.84 | -0.52% |
TEF | 3.84 | -0.52% |
WHL | 5150.00 | -0.44% |
WDI | 0.05 | -37.50% |
F Germany Top Gainers Stocks
F Germany Top Losers Stocks
0FY Daily Charts |
0FY Intraday Charts |
Whats New @ Bazaartrend |
0FY Free Analysis |
|
0FY Important Levels Intraday
RESISTANCE | 0.68 |
RESISTANCE | 0.68 |
RESISTANCE | 0.68 |
RESISTANCE | 0.68 |
RESISTANCE | 0.68 |
RESISTANCE | 0.68 |
RESISTANCE | 0.68 |
RESISTANCE | 0.68 |
0FY Forecast November 2024
4th UP Forecast | 1.07 |
3rd UP Forecast | 0.94 |
2nd UP Forecast | 0.87 |
1st UP Forecast | 0.79 |
1st DOWN Forecast | 0.57 |
2nd DOWN Forecast | 0.49 |
3rd DOWN Forecast | 0.42 |
4th DOWN Forecast | 0.29 |
0FY Weekly Forecast
4th UP Forecast | 0.80 |
3rd UP Forecast | 0.76 |
2nd UP Forecast | 0.74 |
1st UP Forecast | 0.71 |
1st DOWN Forecast | 0.65 |
2nd DOWN Forecast | 0.62 |
3rd DOWN Forecast | 0.60 |
4th DOWN Forecast | 0.56 |
0FY Forecast2024
4th UP Forecast | 5.11 |
3rd UP Forecast | 3.69 |
2nd UP Forecast | 2.81 |
1st UP Forecast | 1.93 |
1st DOWN Forecast | -0.57 |
2nd DOWN Forecast | -1.45 |
3rd DOWN Forecast | -2.33 |
4th DOWN Forecast | -3.75 |
Equillium Inc ( F Germany Symbol : 0FY )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
0FY Other Details
Segment | EQ | |
Market Capital | 145065712.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
0FY Address
0FY Latest News
0FY Business Profile
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. Address: 2223 Avenida De La Playa, La Jolla, CA, United States, 92037
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service